Results 31 to 40 of about 33,657 (222)
Challenges in the Interpretation of Dengue Vaccine Trial Results [PDF]
, 2013 Challenges in the Interpretation of Dengue Vaccine Trial ...
Cummings, Derek A. T. +18 more
core +1 more source
Key Amino Acid Substitution for Infection-Enhancing Activity-Free Designer Dengue Vaccines
iScience, 2019 Summary: Dengue is a globally important disease caused by four serotypes of dengue virus. Dengue vaccine development has been hampered by antigenic cross-reactivity among serotypes, which potentially causes antibody-dependent enhancement of infection and
Atsushi Yamanaka, Eiji Konishi
doaj +1 more source
The pathogenesis of dengue. [PDF]
, 2011 Dengue is an important cause of childhood and adult morbidity in Asian and Latin American countries and its geographic footprint is growing. The clinical manifestations of dengue are the expression of a constellation of host and viral factors, some ...
Whitehorn, J +6 more
core +1 more source
, 2010 INTRODUCTION: Dengue is a vector-borne viral infection that endangers an estimated 2.5 billion people. Disease caused by dengue ranges from a relatively minor febrile illness to a life-threatening condition characterized by extensive capillary leak.
Whitehorn, J +6 more
core +1 more source
International Journal of Infectious Diseases, 2017 Background: Dengue is an important public health problem worldwide. A vaccine has recently been licensed in some countries of Latin America and Asia. Recommendations for dengue vaccine introduction include endemicity and a high serological prevalence of ...
Mabel Carabali +9 more
doaj +1 more source
Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine [PDF]
Mathematical Biosciences, 2017 In this paper we study a mathematical model to analyse the optimal vaccination age against Dengue in Brazil. Data from Brazil are used to estimate the basic reproduction numbers for each of the four Dengue serotypes and then the optimal vaccination age is calculated using a method due to Hethcote [1].
Maier, Sandra B. +5 more
openaire +5 more sources
Monoclonal antibody-based capture ELISA in the diagnosis of previous dengue infection
Virology Journal, 2019 Background Dengue is an important mosquito-borne disease. There is currently only one licensed vaccine for dengue prevention. The vaccine provides higher efficacy in pre-vaccination dengue-seropositive persons but a higher risk of subsequent more severe ...
Chukiat Sirivichayakul +7 more
doaj +1 more source
Dengvaxia: the world’s first vaccine for prevention of secondary dengue
Therapeutic Advances in Vaccines and Immunotherapy, 2021 The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV)
Danielle Tully, Carrie L. Griffiths
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2014 Dengue has emerged as one of the major global public health problems. The disease has broken out of its shell and has spread due to increased international travel and climatic changes. Globally, over 2.5 billion people accounting for >40% of the world's population are at risk from dengue.
Harashish, Jindal +3 more
openaire +2 more sources
Molecular epidemiology of dengue viruses from complete genome sequences [PDF]
, 2010 The availability of the complete genetic blueprint of the dengue virus is essential in molecular epidemiological studies to uncover the role of the virus in dengue pathogenesis.
Ong, Swee Hoe
core +1 more source